We are live on ! Find out more
PRME icon

Prime Medicine
PRME

76 hedge funds and large institutions have $512M invested in Prime Medicine in 2023 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 29 increasing their positions, 6 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

383% more repeat investments, than reductions

Existing positions increased: 29 | Existing positions reduced: 6

157% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 7

15% more funds holding

Funds holding: 66 → 76 (+10)

0.41% more ownership

Funds ownership: 42.51% → 42.92% (+0.41%)

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

33% less capital invested

Capital invested by funds: $768M → $512M (-$256M)

Holders
76
Holders Change
+10
Holders Change %
+15.15%
% of All Funds
1.21%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
18
Increased
29
Reduced
6
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
NAMA
Nikko Asset Management Americas
New York
+$8.33M
2
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group
Japan
+$8.3M
3
GWM
Greenwich Wealth Management
Connecticut
+$5.69M
4
AIM
ARK Investment Management
Florida
+$4.6M
5
WC
Wexford Capital
Florida
+$2.5M

Top Sellers

Rank Fund Capital Flow
1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$24M
2
RG
Redmile Group
California
-$3.53M
3
CCM
CAAS Capital Management
New York
-$1.66M
4
GCM
Ghisallo Capital Management
Massachusetts
-$1.3M
5
PMEF
Point72 Middle East FZE
United Arab Emirates
-$699K
Name Holding Trade Value Shares
Change 		Change in
Stake
Northern Trust
26
Northern Trust
Illinois
$1.11M +$106K +6,533 +8%
Charles Schwab
27
Charles Schwab
California
$903K +$36.5K +2,243 +3%
LCM
28
Laurion Capital Management
New York
$738K – – –
Manulife (Manufacturers Life Insurance)
29
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$561K +$10.5K +642 +1%
Swiss National Bank
30
Swiss National Bank
Switzerland
$515K +$683K +41,900 New
Morgan Stanley
31
Morgan Stanley
New York
$411K +$212K +12,996 +64%
BM
32
Brandywine Managers
Delaware
$406K – – –
JF
33
Jump Financial
Illinois
$400K +$529K +32,500 New
PAM
34
Panagora Asset Management
Massachusetts
$396K +$524K +32,197 New
Bank of New York Mellon
35
Bank of New York Mellon
New York
$370K +$17.1K +1,052 +4%
TD Asset Management
36
TD Asset Management
Ontario, Canada
$294K – – –
California State Teachers Retirement System (CalSTRS)
37
California State Teachers Retirement System (CalSTRS)
California
$258K +$274K +16,823 +406%
CSS
38
Cubist Systematic Strategies
Connecticut
$242K +$302K +18,539 +1,649%
State of Wisconsin Investment Board
39
State of Wisconsin Investment Board
Wisconsin
$221K +$293K +17,999 New
CGL
40
Clarius Group LLC
Washington
$198K – – –
OC
41
Oppenheimer & Co
New York
$186K +$18K +1,106 +8%
RLIM
42
Red Lighthouse Investment Management
New York
$184K +$244K +14,950 New
CS
43
Credit Suisse
Switzerland
$181K +$227K +13,905 +1,738%
Capstone Investment Advisors
44
Capstone Investment Advisors
New York
$179K +$237K +14,551 New
N
45
Nuveen
North Carolina
$174K – – –
Janus Henderson Group
46
Janus Henderson Group
United Kingdom
$173K +$230K +14,091 New
JP Morgan Chase
47
JP Morgan Chase
New York
$159K +$49.2K +3,023 +31%
Deutsche Bank
48
Deutsche Bank
Germany
$134K +$104K +6,387 +143%
Millennium Management
49
Millennium Management
New York
$132K +$175K +10,759 New
SIM
50
Sandia Investment Management
Massachusetts
$123K – – –
1
2
3 4

PRME Hedge Fund Activity: Q1 2023 in Review

76 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Prime Medicine (PRME) for Q1 2023, worth a combined $512M — down 33% from $768M a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new PRME positions and 7 closed out — a net gain of 11 holders — while 29 added to existing stakes and 6 trimmed.

The largest buyer was Nikko Asset Management Americas, adding an estimated $8.33M. The largest seller was T. Rowe Price Associates, cutting an estimated $24M.

  • 76 institutional investors held Prime Medicine (PRME) as of Q1 2023, up from 66 in Q4 2022.
  • Funds reported $512M of Prime Medicine stock for Q1 2023, down 33% quarter-over-quarter.
  • 18 funds opened new Prime Medicine positions in Q1 2023 and 7 closed out, a net change of +11 holders.
  • The largest Prime Medicine buyer in Q1 2023 was Nikko Asset Management Americas, an estimated $8.33M added.
  • The largest Prime Medicine seller in Q1 2023 was T. Rowe Price Associates, an estimated $24M sold.

Based on aggregated 13F filings for Q1 2023.